With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge
admin 13th April 2018 Uncategorised 0With both Merck and Bristol-Myers Squibb rolling out closely watched data on their immuno-oncology contenders at a medical meeting this weekend, one thing’s for sure: Investors will be drawing comparisons. And while those comparisons may not be totally fair, one analyst has already tapped Merck as the early winner.
More: With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge
Source: fierce